Literature DB >> 2703484

Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins.

R C Stephenson1, S Clarke.   

Abstract

Nonenzymatic intramolecular reactions can result in the deamidation, isomerization, and racemization of protein and peptide asparaginyl and aspartyl residues via succinimide intermediates. To understand the sequence dependence of these reactions, we measured the rate of succinimide formation in a series of synthetic peptides at pH 7.4. These peptides (Val-Tyr-Pro-X-Y-Ala) contained an internal aspartyl, asparaginyl, aspartyl beta-methyl ester, or aspartyl alpha-methyl ester residue (X) followed by a glycyl, seryl, or alanyl residue (Y). The rates of succinimide formation of the asparaginyl peptides were found to be 13.1-35.6 times faster than those of the aspartyl peptides. The rates of succinimide formation for the glycyl peptides were 6.5-17.6 times faster than those of the alanyl peptides, while the rates for the seryl peptides were 1.6-4.5 times faster than those of the alanyl peptides. The overall 232-fold range in these reaction rates for aspartyl and asparaginyl residues suggests that sequence can be an important determinant in their stability in flexible peptides. In proteins, there may be a much larger range in the rates of succinimide formation because specific conformations may greatly enhance or inhibit this reaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  118 in total

1.  The effects of alpha-helix on the stability of Asn residues: deamidation rates in peptides of varying helicity.

Authors:  A A Kosky; U O Razzaq; M J Treuheit; D N Brems
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides.

Authors:  K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 3.  Virus maturation.

Authors:  David Veesler; John E Johnson
Journal:  Annu Rev Biophys       Date:  2012-02-23       Impact factor: 12.981

4.  Identification and characterization of an anti-isoaspartic acid monoclonal antibody.

Authors:  S R Lehrman; D M Hamlin; M E Lund; G A Walker
Journal:  J Protein Chem       Date:  1992-12

5.  Large-scale, pH-dependent, quaternary structure changes in an RNA virus capsid are reversible in the absence of subunit autoproteolysis.

Authors:  Derek J Taylor; Neel K Krishna; Mary A Canady; Anette Schneemann; John E Johnson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  An innovative approach for the characterization of the isoforms of a monoclonal antibody product.

Authors:  Shanmuuga Sundaram; Alice Matathia; Jun Qian; Jingming Zhang; Ming-Ching Hsieh; Tun Liu; Richard Crowley; Babita Parekh; Qinwei Zhou
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

7.  Mitochondrial complex I in the post-ischemic heart: reperfusion-mediated oxidative injury and protein cysteine sulfonation.

Authors:  Patrick T Kang; Chwen-Lih Chen; Paul Lin; Liwen Zhang; Jay L Zweier; Yeong-Renn Chen
Journal:  J Mol Cell Cardiol       Date:  2018-07-20       Impact factor: 5.000

8.  Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state.

Authors:  Bei Li; Richard L Schowen; Elizabeth M Topp; Ronald T Borchardt
Journal:  AAPS J       Date:  2006-03-20       Impact factor: 4.009

9.  Estimation of age at death based on aspartic acid racemization in elastic cartilage of the epiglottis.

Authors:  Christian Matzenauer; Alexandra Reckert; Stefanie Ritz-Timme
Journal:  Int J Legal Med       Date:  2013-11-12       Impact factor: 2.686

10.  Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11.

Authors:  Wei Zhang; J Marta J Czupryn; Philip T Boyle; John Amari
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.